European journal of clinical investigation
-
Eur. J. Clin. Invest. · May 2024
Abnormal circulating steroids refine risk of progression to heart failure in ischemic heart disease.
Patients with ischemic heart disease (IHD) experience a high incidence of progression to heart failure (HF) despite current therapies. We speculated that steroid hormone metabolic disorders distinct adverse phenotypes and contribute to HF. ⋯ A steroid-based strategy can simply and effectively identify individuals at higher HF risk who may derive benefit from more intensive follow-ups.
-
Eur. J. Clin. Invest. · May 2024
The association between the basal metabolic rate and cardiovascular disease: A two-sample Mendelian randomization study.
Mendelian randomization analysis was applied to elucidate the causal relationship between the basal metabolic rate (BMR) and common cardiovascular diseases. ⋯ Our study reveals a possible causal effect of BMR on the risk of cardiomyopathy, heart failure and valvular disease, but not for coronary disease and AF.
-
Eur. J. Clin. Invest. · May 2024
Hydrocortisone cardioprotection in ischaemia/reperfusion injury involves antioxidant mechanisms.
Glucocorticoid (GR) and mineralocorticoid (MR) receptors are highly expressed in cardiac tissue, and both can be activated by corticosteroids. MR activation, in acute myocardial infarction (AMI), worsens cardiac function, and increase NHE activity contributing to the deleterious process. In contrast, effects of GR activation are not fully understood, probably because of the controversial scenario generated by using different doses or potencies of corticosteroids. ⋯ Our results provide the first evidence that acute HC treatment during early reperfusion induces cardioprotection against AMI, associated with a non-genomic HC-triggered NHE1 inhibition by AKT and antioxidant action that might involves mitochondrial dynamics improvement.